Antyhypoxic effect of cell juice of first

The pre-clinical study of the antihypoxic effect of cell juice of the Siberian fir was conducted in the Research Institute of Hygiene (Novosibirsk) in laboratory mice.

Under conditions of oxygen deficiency in mice, the introduction of the extract increased the life time to 32% compared with the control group receiving water. The hypoxic exposure caused a stress reaction, as in immobilization stress. The water extract protected internal organs, restored the content of white blood cells that was reduced against the background of hypoxic stress, cells of bone marrow, spleen, and thymus.

Urazova L.N.1 Sultanov V.S.2 Kuznetsova T.I.1 Kuznetsova T.I.1 Roshchin V.I.3 Nikitina T.V. Research Institute of Oncology of the Siberian Branch of the Russian Academy of Medical Sciences, Tomsk, Russia Solagran Limited, Melbourne, Australia S.M. Kirov Academy of Forestry Engineering in St. Petersburg, St. Petersburg, Russia I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Petersburg, Russia


In recent years, a significant amount of data has accumulated on the application of biological response modifiers in the therapy of oncological diseases, including those of vegetable origin, that increase the anti-tumor resistance of the organism by impacting its regulatory structures. Preliminary studies showed that the studied polyprenolic preparation* obtained from the fir needles of the fir tree (Picea abies L. karst) and containing polyprenols as an active substance, can also enhance the induction of interferon in the blood serum in animals, and this effect is of prolonged nature. Since the anti-tumor effects of IFN drugs and their inductors have long been used in clinical practice, it seemed topical to conduct an experimental study of the anti-tumor activity of polyprenols*.

Study Purpose

Determining the effectiveness of application of polyprenols* in the mono- and combination therapy of malignant tumors in the experiment.


The research was carried out in mice of the C57B1/6 line with the weight of 18-20 g. An Ehrlich adenocarcinoma and an hematogenously metastazing Lewis lung carcinoma were used as experimental models. A solution of a polyprenolic drug* in the doses of 25.0 mg/kg and 12.5 mg/kg was administered orally to animals within 14 days. The alkylating cytostatic agent of cyclophosphan was administered intraperitoneally in the total dose of 180 mg/kg. The dynamics of the tumor growth, metastasis inhibition index (MII) and the life span of animals were assessed. The results were statistically processed using STATISTICA 6.0 software package.


An insignificant independent anti-tumor activity of polyprenols* that depended on the drug dosage and the stage of oncogenesis was found on the models of a solid variant of Ehrlich tumors and Lewis lung carcinoma. It was established that the volume of tumors with the complex use of a polyprenol drug* against the background of a cytostatic agent were 4.2 times lower than the control and 1.4 times lower than the group of mice which were only treated with cyclophosphan. It is necessary to note the positive effect of polyprenols* in the combination therapy with cyclophosphan in relation to the intensity of metastasis. The MII is more pronounced in the group of animals treated with a complex therapy, than in the group receiving only a cytostatic agent (85.9% vs. 71.8%). The ability of polyprenols* to increase the life span of mice by 50% in comparison with the control and by 25% in comparison with cyclophosphan was shown on the model of a solid Ehrlich carcinoma. An independent, as against the background of cytostatic therapy, ability of polyprenols* to significantly increase the life span of experimental animals in comparison with the control was shown on the model of a Lewis lung carcinoma. It is comparable only with a similar cytostatic therapy, which indirectly testifies to the decrease of toxicity of the cytostatic agent. Conclusions. The findings suggest the possibility of applying a polyprenol drug* in the clinical oncology as a remedy increasing the span of life and improving its quality. Polyprenols* also reduce the total toxic effect of a cytostatic agent, without lowering its anti-tumor activity. (Published in the proceedings of the International Conference of "Development of Scientific Research and Surveillance of Infectious Diseases"/edited by A.B. Zhebrun. — SPb.: Louis Pasteur Research Institute of Epidemiology and Microbiology in St. Petersburg, Federal Budgetary Institution of Science of Rospotrebnadzor (Federal Service for Supervision of Consumer Rights Protection and Human Well-Being), 2010.)

* The polyprenol drug of Ropren, which is a pure concentrate of polyprenols (the total fraction of 95%) was used in the study. The text of the study is provided by courtesy of Solagran.